Please login to the form below

Accelerating HTA and payer submissions: how digital connectivity is driving faster patient access

Sotiria Papanicolaou, Chief Consulting Officer at PRMA Consulting, a member of Fishawack Health, explains how the combination of digital innovation and expert insight are removing roadblocks and speeding up the generation of health technology assessments (HTA) and payer submissions for pharma.

The road to health technology assessments and payer submissions is paved with complexity. Pharma’s mission is simple: to minimize the time between regulatory approval and market access, ensuring in the process that a drug is accessible to all appropriate patients, in line with the regulatory approval.

However, the journey is often slowed down by roadblocks with significant business risk and potential delays to patient access. These could easily be avoided with better navigation and greater collaboration. Thankfully, the digital solution to guide us home is already out there.

Navigating the heavy traffic of developing HTA and payer submissions

But first, let’s look at the current driving conditions. At the affiliate level, the roads are congested. Busy access teams are hurriedly moving from lane to lane, simultaneously managing submissions across multiple therapy areas, products, and indications. For each HTA and payer submission, they need to:

  • Construct strong value arguments that meet evolving local payer requirements
  • Develop innovative pricing and contracting models that resonate with local stakeholder needs
  • Manage limited time and resources

With so much to do, teams often only get the chance to review global materials for each submission as they join the approach road to launch. The global value dossiers (GVDs) they are given are usually well‑defined and provide solid directions. But with limited time to consult the map, teams are sometimes pulling out onto unfamiliar roads and quickly finding themselves held up in traffic. Global teams need to provide effective support and materials to ensure that global strategy is incorporated into local submissions.

Everyone needs help—from improving the GVD to strengthening alignment between global and local teams. With a better navigation system, and closer collaboration, it is possible to plan a faster route.


28th October 2021



Company Details

Fishawack Health

+44 20 3328 1840

Contact Website

No. 3 Booths Park
Booths Hall
Chelford Road
WA16 8GS
United Kingdom

Latest content on this profile

The challenges of reimbursement and innovative pricing for cell and gene therapies
Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of innovative pricing models, including ensuring the model chosen meets the payer’s needs.
Fishawack Health
Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes
Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech giants dominate?
Fishawack Health
Fishawack Health welcomes Mario Muredda as its new President of Marketing
Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.
Fishawack Health
5 ways we’re enhancing our services to support our clients in 2023
Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023.
Fishawack Health
Why it’s time to apply a payer lens to your early pipeline planning
Value, evidence, and market access experts Jan McKendrick and Andrea Hamlin reveal why applying a payer lens early in the value assessment of pipeline assets is essential for driving commercial success.
Fishawack Health
The fast-paced future of cell and gene therapies
In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist teams.
Fishawack Health